Zachary Bessette

GU Oncology Now

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) published a <a href="https://s3.amazonaws.com/rdcms-snmmi/files/production/public/FileDownloads/AUC/PSMA-617%20appropriate%20use%204.26.23%20-%20Final%20Approved.pdf" target="_blank" rel="noopener">new consensus statement</a> in the Journal of Nuclear Medicine that provides recommendations for the selection and management of patients with metastatic castration-resistant prostate cancer (mCRPC) who are being treated with 177Lu-PSMA radionuclide therapy.177Lu-PSMA-617 is approved by the US Food and Drug Administration for the treatment of patients with mCRPC after disease progression on taxane-based chemotherapy and at least 1 prior line of androgen receptor pathway inhibitors (ARPIs). SNMMI convened an autonomous workgroup comprising a multidisciplinary panel of health care professionals to review 4 prospective phase 2/3 clinical trials that used 177Lu-PSMA-617 and develop consensus recommendations.Regarding patient selection, the workgroup recommends that PSMA PET (18F-DCFPyL or 68Ga-PSMA-11) should be performed within 3 months of treatment or reported disease progression on the most recent therapy to ensure that the current disease state is represented. 18F-FDG PET is not required as a standard patient selection tool, they added, and patients should be imaged with either contrast-enhanced CT or MRI to identify PSMA-negative disease.As for treatment sequencing, the workgroup deemed 177Lu-PSMA after chemotherapy and ARPI as &ldquo;appropriate,&rdquo; while administration after ARPI and before chemotherapy is &ldquo;rarely appropriate.&rdquo; Additionally, they noted the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) with 177Lu-PSMA is &ldquo;rarely appropriate.&rdquo;Included in the consensus statement is a section on the current clinical struggles that physicians face when administering 177Lu-PSMA, including subsections for the role of androgen receptor-targeted therapies, the role of Radium-223, treatment-related toxicities, when to consider cessation of treatment, exceptional responders and restarting treatment, and imaging during treatment.&ldquo;How to determine when to stop treatment remains a difficult decision,&rdquo; statement authors wrote. &ldquo;We look forward to the potential use of PSMA [radionuclide therapy] in prechemotherapy mCRPC or other settings pending the full results of ongoing trials,&rdquo; they added, listing the PSMAfore, SPLASH, and ECLIPSE trials in the prechemotherapy setting; PSMAddition in the mCSPC setting; and numerous nonregistration trials evaluating 177Lu-PSMA-617 in combination with immunotherapy, chemotherapy, ARPIs, and DNA damage repair pathways.

SNMMI Issues Consensus Statement on Patient Selection, Appropriate Use of Lu-177 PSMA-617

Metastatic castration-resistant prostate cancer 

CRPC

The new consensus statement provides recommendations for the selection and management of patients with mCRPC who are treated with 177Lu-PSMA.

SNMMI Issues Consensus Statement for Lu-177 PSMA-617

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe